Home/Filings/4/0001415889-24-027709
4//SEC Filing

Manning Paul B 4

Accession 0001415889-24-027709

CIK 0001660334other

Filed

Nov 25, 7:00 PM ET

Accepted

Nov 26, 4:15 PM ET

Size

22.4 KB

Accession

0001415889-24-027709

Insider Transaction Report

Form 4
Period: 2024-11-22
Manning Paul B
Director10% Owner
Transactions
  • Purchase

    Series A Warrants (right to buy)

    2024-11-22+9,213,4839,213,483 total
    Exercise: $1.07From: 2024-11-22Exp: 2025-11-22Common Stock (9,213,483 underlying)
  • Purchase

    Common Stock

    2024-11-22+18,426,96626,278,094 total
  • Purchase

    Series B Warrants (right to buy)

    2024-11-22+9,213,4839,213,483 total
    Exercise: $1.33From: 2024-11-22Exp: 2029-11-22Common Stock (9,213,483 underlying)
  • Purchase

    Series A Warrants (right to buy)

    2024-11-22+2,247,1912,247,191 total(indirect: See footnote)
    Exercise: $1.07From: 2024-11-22Exp: 2025-11-22Common Stock (2,247,191 underlying)
  • Purchase

    Series B Warrants (right to buy)

    2024-11-22+2,247,1912,247,191 total(indirect: See footnote)
    Exercise: $1.33From: 2024-11-22Exp: 2029-11-22Common Stock (2,247,191 underlying)
  • Purchase

    Common Stock

    2024-11-22+4,494,3825,976,101 total(indirect: See footnote)
  • Gift

    Common Stock

    2024-11-26450,00025,828,094 total
Holdings
  • Common Stock

    (indirect: See footnote)
    256,634
  • Common Stock

    (indirect: By Trust)
    891,870.42
  • Common Stock

    (indirect: By Trust)
    3,324,338.75
  • Common Stock

    (indirect: By Trust)
    891,870.41
  • Common Stock

    (indirect: By Trust)
    891,870.42
Footnotes (7)
  • [F1]The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
  • [F2]The shares are held by Mr. Manning jointly with his spouse.
  • [F3]The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC ("BKB") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock.
  • [F4]The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
  • [F5]These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  • [F6]The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
  • [F7]The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.

Issuer

Verrica Pharmaceuticals Inc.

CIK 0001660334

Entity typeother

Related Parties

1
  • filerCIK 0001494695

Filing Metadata

Form type
4
Filed
Nov 25, 7:00 PM ET
Accepted
Nov 26, 4:15 PM ET
Size
22.4 KB